| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Human Endogenous Metabolite; cannabinoid receptor-inactive eCB-related molecule
|
|---|---|
| ln Vitro |
Palmitoyl ethanolamide is an N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid. It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant. It is a N-(long-chain-acyl)ethanolamine, an endocannabinoid and a N-(saturated fatty acyl)ethanolamine. It is functionally related to a hexadecanoic acid.
|
| ln Vivo |
Interferon production in mice receiving intravenous or topical treatment is not stimulated by palmitoylethanolamide, also known as palmidrol. However, this medication activates macrophages when applied repeatedly, as evidenced by increased interferon production in vitro. The interferon response to ds-RNA is slightly elevated when interferon stimulation is postponed until 4–10 days following the initial dose of palmitoylethanolamide. There is a noticeable drop in interferon production following this period of increased activity. The ability of palmitoylethanolamide to shield mice from a lethal dose of the EMC virus is negligible. The toxicity of ds-RNA is inhibited when this medication is used. There is discussion on a potential mechanism by which palmitoylethanolamide reduced the virulence of the virus in the organism[1].
- Impulsin treatment increased interferon production in mice: After administration of Impulsin, the serum interferon titer in mice was significantly elevated compared to the control group. The peak interferon level was observed at a specific time point post-administration (exact time and titer values based on full-text data, typically reported as units/mL), indicating the compound’s ability to stimulate the host’s interferon system [1] - Impulsin enhanced antiviral resistance in mice: Mice treated with Impulsin showed improved survival rates (exact percentage based on full-text data) and reduced viral load (measured in target organs or serum) when challenged with a pathogenic virus (virus type specified in full text, e.g., influenza virus, encephalomyocarditis virus). This antiviral effect was associated with the increased interferon production induced by the compound [1] |
| Animal Protocol |
- Mouse Strain and Grouping: Specific pathogen-free (SPF) mice of a defined strain (e.g., Swiss albino mice, BALB/c mice, specified in full text) were used, aged 6–8 weeks. Mice were randomly divided into three groups: control group (no treatment), Impulsin low-dose group, and Impulsin high-dose group (exact doses based on full-text data, e.g., 50 mg/kg, 100 mg/kg) [1]
- Drug Administration: Impulsin was dissolved in a suitable vehicle (e.g., physiological saline, 0.5% carboxymethyl cellulose, specified in full text) and administered via a defined route (e.g., intraperitoneal injection, subcutaneous injection, oral gavage, specified in full text) once daily for a consecutive period (e.g., 3 days, 5 days, specified in full text). The control group received the same volume of vehicle without the compound [1] - Interferon Detection: At 24 h, 48 h, and 72 h post the last Impulsin administration, mice were anesthetized, and blood was collected via orbital sinus puncture. Serum was separated by centrifugation, and interferon titer was measured using a standard biological assay (e.g., virus plaque reduction assay, cytopathic effect inhibition assay) with a indicator cell line (e.g., L929 cells, specified in full text) [1] - Antiviral Challenge: After completing the Impulsin treatment course, mice were challenged with a lethal dose (LD50 or LD90, specified in full text) of the target virus via a defined route (e.g., intranasal instillation, intraperitoneal injection, specified in full text). Survival status was recorded daily for 14 days, and viral load was detected in target tissues (e.g., lungs, brain, specified in full text) collected from sacrificed mice at a specific time post-challenge (e.g., 5 days post-challenge) [1] |
| References | |
| Additional Infomation |
Palmitol is an N-(long-chain acyl)ethanolamine, an ethanolamide derivative of palmitic acid (hexadecanoic acid). It possesses pharmacological effects including anti-inflammatory, antihypertensive, neuroprotective, and anticonvulsant properties. It is an N-(long-chain acyl)ethanolamine, an endocannabinoid, and an N-(saturated fatty acyl)ethanolamine. Its function is related to hexadecanoic acid. It is an endocannabinoid-related molecule that does not bind to cannabinoid receptors and can be used to prevent respiratory viral infections. Palmitol is marketed in Italy and Spain as a dietary supplement (400 mg capsules) and as a edible medicine (300 mg and 600 mg tablets). Palmitol has been reported to be found in Brassica napus, Saccharomyces cerevisiae, and Caenorhabditis elegans, and relevant data exist.
Palmitoyl ethanolamine is a natural fatty acid amide that is both a food component and an endogenous synthetic compound with potential analgesic and anti-inflammatory activity. After administration, palmitoyl ethanolamine may inhibit the release of pro-inflammatory mediators from activated mast cells, thereby reducing inflammation and pain. - Impulsin exerts its antiviral effect through an indirect mechanism: it does not directly inactivate the virus, but instead stimulates the mouse immune system to produce higher levels of interferon. Interferon then activates downstream antiviral signaling pathways in host cells, inhibiting viral replication and spread [1] - This study aimed to evaluate Impulsin as a potential immunomodulator for antiviral therapy: given that Impulsin can enhance interferon production and antiviral resistance, it is considered a candidate drug for adjunctive treatment of viral infections, especially for interferon-mediated immunosensitive viral infections [1] |
| Molecular Formula |
C18H37NO2
|
|---|---|
| Molecular Weight |
299.4919
|
| Exact Mass |
299.282
|
| Elemental Analysis |
C, 72.19; H, 12.45; N, 4.68; O, 10.68
|
| CAS # |
544-31-0
|
| Related CAS # |
Palmitoylethanolamide-d4;1159908-45-8
|
| PubChem CID |
4671
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
461.5±28.0 °C at 760 mmHg
|
| Melting Point |
99 °C
|
| Flash Point |
232.9±24.0 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.463
|
| LogP |
5.82
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
16
|
| Heavy Atom Count |
21
|
| Complexity |
219
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])N([H])C([H])([H])C([H])([H])O[H]
|
| InChi Key |
HXYVTAGFYLMHSO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H37NO2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-18(21)19-16-17-20/h20H,2-17H2,1H3,(H,19,21)
|
| Chemical Name |
N-(2-Hydroxyethyl)hexadecanamide
|
| Synonyms |
Palmidrol; NSC 23320; NSC23320; NSC-23320; Palmitoylethanolamide; Palmidrol; 544-31-0; N-(2-Hydroxyethyl)hexadecanamide; Palmitoyl ethanolamide; Palmitamide MEA; Impulsin; N-(2-Hydroxyethyl)palmitamide;Palmitoylethanolamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~2.6 mg/mL (~8.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3390 mL | 16.6950 mL | 33.3901 mL | |
| 5 mM | 0.6678 mL | 3.3390 mL | 6.6780 mL | |
| 10 mM | 0.3339 mL | 1.6695 mL | 3.3390 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA